Drug Type Small molecule drug |
Synonyms IPG 007, IPG 7236, IPG-007 + [3] |
Target |
Action inhibitors |
Mechanism CCR8 inhibitor(C-C chemokine receptor type 8 inhibitor) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H31N3O3S |
InChIKeyPDAOEKSLYKFTKF-SFHVURJKSA-N |
CAS Registry2756350-93-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Head and Neck Neoplasms | Phase 2 | United States | 30 Dec 2021 | |
Kidney Neoplasms | Phase 2 | United States | 30 Dec 2021 | |
Melanoma | Phase 2 | United States | 30 Dec 2021 | |
Triple Negative Breast Cancer | Phase 2 | United States | 30 Dec 2021 | |
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 15 Nov 2021 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 15 Nov 2021 | |
Dermatitis, Atopic | Phase 1 | Australia | 11 Apr 2022 | |
Immunoglobulin G4-Related Disease | Phase 1 | China | 30 Jan 2022 |